{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:38:38Z","timestamp":1770817118631,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.bone.2009.07.089","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T07:24:07Z","timestamp":1249975447000},"page":"1044-1052","source":"Crossref","is-referenced-by-count":36,"title":["A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy"],"prefix":"10.1016","volume":"45","author":[{"given":"A.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2009.07.089_bib1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/13543784.15.9.1091","article-title":"Lasofoxifene: a third-generation selective estrogenreceptor modulator for the prevention and treatment of osteoporosis","volume":"15","author":"Gennari","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bone.2009.07.089_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1358\/dot.2006.42.6.973583","article-title":"Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis","volume":"42","author":"Gennari","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bone.2009.07.089_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1359\/jbmr.2001.16.4.765","article-title":"Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats","volume":"16","author":"Ke","year":"2001","journal-title":"J Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.07.089_bib4","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1210\/en.2003-1481","article-title":"Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats","volume":"145","author":"Ke","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2009.07.089_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.bone.2009.07.089_bib6","unstructured":"Cummings, S.R., Eastell, R., Ensrud, K., Reid, D.M., Vukicevic, S., LaCroix, A., et al., The effects of lasofoxifene on fractures and breast cancer; three year results from the PEARL trial. J. Bone Miner. Res. 23, S81. 1-9-0008. Ref Type: Abstract."},{"key":"10.1016\/j.bone.2009.07.089_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02556113","article-title":"Precision and stability of dual-energy X-ray absorptiometry measurements","volume":"49","author":"Johnson","year":"1991","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2009.07.089_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.07.089_bib9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bone.2008.01.021","article-title":"Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy","volume":"42","author":"Reginster","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.07.089_bib10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.07.089_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.07.089_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2009.07.089_bib13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2009.07.089_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"Braga de Castro","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.07.089_bib15","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.clinthera.2007.09.017","article-title":"Effects of risedronate 5\u00a0mg\/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial","volume":"29","author":"Valimaki","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2009.07.089_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.07.089_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1210\/jc.85.6.2197","article-title":"A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women","volume":"85","author":"Prestwood","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.07.089_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.07.089_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/S002966510800699X","article-title":"Biomarkers of bone health and osteoporosis risk","volume":"67","author":"Eastell","year":"2008","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.bone.2009.07.089_bib20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.07.089_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209017906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209017906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T21:26:29Z","timestamp":1545081989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328209017906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S8756328209017906"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2009.07.089","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}